A polymerizable monomer prepared by reacting at least one epoxidized cardanol with (meth)acrylic anhydride or (meth)acryloyl chloride in the presence of one or more of triethylamine, tertiary amines, pyridines and pyridine derivatives; wherein the epoxidized cardanol is formed by epoxidation of an unsaturation site of a cardanol having the formula:

##STR00001##

wherein R is selected from hydrogen and an alkyl, or alkenyl group having 1-6 carbon atoms, and n is 7, 10, or 13, a polymer and resin made form the polymerizable monomer, and a method of preparing such a polymer. The resin created from this monomer is suitable for moderate temperature composites and coatings applications.

A polymerizable monomer prepared by reacting at least one epoxidized cardanol with (meth)acrylic anhydride or (meth)acryloyl chloride in the presence of one or more of triethylamine, tertiary amines, pyridines and pyridine derivatives; wherein the epoxidized cardanol is formed by epoxidation of an unsaturation site of a cardanol having the formula:

##STR00001##

wherein R is selected from hydrogen and an alkyl, or alkenyl group having 1-6 carbon atoms, and n is 7, 10, or 13, a polymer and resin made form the polymerizable monomer, and a method of preparing such a polymer. The resin created from this monomer is suitable for moderate temperature composites and coatings applications.

Compounds and methods related to the prevention and treatment of diseases and conditions, some of which are facilitated by melanogenesis are disclosed. Specifically, the present subject matter includes a series of compounds and compositions and their use for anti-melanogenic and antioxidant activity. This subject matter also includes the treatment of skin disorder due to acne vulgaris and related inflammatory and post inflammatory hyperpigmentation. Methods for synthesizing contemplated compounds are also disclosed.

An improved method for making cannabigerol (CBG) utilizing the following steps. CBG-containing material is contacted with an aqueous alkaline solution containing a hydroxide base and essentially no organic solvents, thereby extracting cannabinoids including carboxylic acids and salts and producing an alkaline extract. Non-soluble CBG-containing material is removed from the alkaline extract to produce a clarified alkaline extract. The extracted cannabinoids are decarboxylated and the resulting cannabigerol is crystallized/precipitated from the clarified alkaline extract at a pH greater than 7.

An improved method for making cannabigerol (CBG) utilizing the following steps. CBG-containing material is contacted with an aqueous alkaline solution containing a hydroxide base and essentially no organic solvents, thereby extracting cannabinoids including carboxylic acids and salts and producing an alkaline extract. Non-soluble CBG-containing material is removed from the alkaline extract to produce a clarified alkaline extract. The extracted cannabinoids are decarboxylated and the resulting cannabigerol is crystallized/precipitated from the clarified alkaline extract at a pH greater than 7.

A method for producing bisphenol A (BPA) is provided. The method includes step A of degrading a polycarbonate resin in a solvent and distilling off the solvent to obtain a crude solution A; step B of subjecting acetone and phenol to dehydration condensation; step C of distilling off unreacted acetone and water to obtain a concentrated liquid C; step D of crystallizing the concentrated liquid C to obtain a slurry liquid, from which a mother liquor D is obtained; step H of obtaining a solution H1 or a solution H2 from the crude solution A and part of the mother liquor D; and step I of supplying the solution H1 or H2 to the step B or C. The solution H1 contains BPA obtained by degrading BPA contained in the crude solution A and the mother liquor D into phenol and isopropenylphenol and then rebonding phenol and isopropenylphenol, and the solution H2 contains phenol obtained by degrading BPA contained in the crude solution A and the mother liquor D into phenol and acetone.

A method for producing bisphenol A (BPA) is provided. The method includes step A of degrading a polycarbonate resin in a solvent and distilling off the solvent to obtain a crude solution A; step B of subjecting acetone and phenol to dehydration condensation; step C of distilling off unreacted acetone and water to obtain a concentrated liquid C; step D of crystallizing the concentrated liquid C to obtain a slurry liquid, from which a mother liquor D is obtained; step H of obtaining a solution H1 or a solution H2 from the crude solution A and part of the mother liquor D; and step I of supplying the solution H1 or H2 to the step B or C. The solution H1 contains BPA obtained by degrading BPA contained in the crude solution A and the mother liquor D into phenol and isopropenylphenol and then rebonding phenol and isopropenylphenol, and the solution H2 contains phenol obtained by degrading BPA contained in the crude solution A and the mother liquor D into phenol and acetone.

The present disclosure provides methods for selectively crystallizing cannabinoids from solutions containing a plurality of cannabinoids. The present disclosure further provides methods for separating a crystallized cannabinoid from a mixture of cannabinoids.

The present disclosure provides methods for selectively crystallizing cannabinoids from solutions containing a plurality of cannabinoids. The present disclosure further provides methods for separating a crystallized cannabinoid from a mixture of cannabinoids.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and/or prevention of malign skin disorders, in particular skin cancer.